GSK reported Phase 3 results for bepirovirsen (B-Well 1 and B-Well 2) in chronic hepatitis B, saying 19% to 20% of treated patients achieved a functional cure after stopping nucleos(t)ide analog therapy. GSK framed the outcome as a potential step toward deeper, fixed-duration regimens in a field where “functional cure” remains the key clinical endpoint. In the trials, none of the placebo-assigned patients met the functional cure definition. Treatment was associated with higher adverse-event rates, including alanine aminotransferase elevations, with grade 3 or higher events in 16% of the bepirovirsen group versus 3% on placebo—data that will shape clinician risk-benefit discussions and regulator review.